Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
November 18 2021 - 4:01PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
it will host a virtual R&D Day on Tuesday, December 7, 2021
from 10:00 a.m. to 12:00 p.m. ET.
“We are pleased to announce that the IND application for
ATI-2138, an investigational oral small molecule ITK/TXK/JAK3 (ITJ)
inhibitor, for the treatment of psoriasis has been allowed by the
U.S. Food and Drug Administration and we are very excited about our
plans to progress this third novel compound from our proprietary
KINect® drug discovery platform into clinical development,” said
Dr. Neal Walker, President & CEO of Aclaris. “We look forward
to providing more details about this clinical program and our other
pipeline assets at our upcoming virtual R&D Day in early
December.”
The virtual R&D Day, intended for investors and analysts,
will include the following topics:
- Zunsemetinib (ATI-450), an Investigational Oral MK2
Inhibitor
- ATI-2231, an Investigational Oral MK2 Inhibitor
- ATI-2138, an Investigational ITJ Inhibitor
- Oral Gut-restricted Discovery Program
Conference Call and Webcast
Management will host the event via conference call and webcast,
with an accompanying slide presentation. To participate in the
call, please dial (844) 776-7782 (domestic) or (661) 378-9535
(international) and reference conference ID 7675751. A webcast of
the event may be accessed through the “Events” page of the
“Investors” section of Aclaris’ website, www.aclaristx.com. The
webcast will be archived for at least 30 days on the Aclaris
website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris’ current beliefs
and expectations. These forward-looking statements include Aclaris’
plans for the clinical development of ATI-2138. These statements
involve risks and uncertainties that could cause actual results to
differ materially from those reflected in such statements. Risks
and uncertainties that may cause actual results to differ
materially include uncertainties inherent in the conduct of
clinical trials, Aclaris’ reliance on third parties over which it
may not always have full control, Aclaris’ ability to enter into
strategic partnerships on commercially reasonable terms, the
uncertainty regarding the COVID-19 pandemic and other risks and
uncertainties that are described in the Risk Factors section of
Aclaris’ Annual Report on Form 10-K for the year ended December 31,
2020 and other filings Aclaris makes with the U.S. Securities and
Exchange Commission from time to time. These documents are
available under the “SEC Filings” page of the “Investors” section
of Aclaris’ website at www.aclaristx.com. Any forward-looking
statements speak only as of the date of this press release and are
based on information available to Aclaris as of the date of this
release, and Aclaris assumes no obligation to, and does not intend
to, update any forward-looking statements, whether as a result of
new information, future events or otherwise.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024